Abstract:Abstract Background Malignant nephrosclerosis, defined as renal microangiopathy in the setting of severe hypertension, remains a critical renal emergency leading to end-stage renal disease despite aggressive anti-hypertensive treatment. Recently, activation of the complement alternative pathway (AP) has been reported to play a prominent role in the pathogenesis of malignant nephrosclerosis. However, subsequent study failed to recapitulate the findings of genetic complement abnormalities in the disease. This study aimed to determine the presence of AP activation and genetic complement defects and establish their correlations to renal microangiopathy lesions, clinical features and prognosis in patients with malignant nephrosclerosis. Methods Fifty patients with malignant hypertension and concomitant thrombotic microangiopathy (TMA) proven by renal biopsy were investigated; 25 cases of kidney donors who received zero-hour allograft biopsies were used as normal controls. Various renal TMA lesions in patients with malignant nephrosclerosis were reviewed and evaluated using a semi-quantitative scoring system. Deposition of C5b-9, C3a, C5a, C4d and mannose-binding lectin was assessed by immunohistochemistry. Co-localization of C5b-9 and CD34 was detected by confocal microscopy. Complement factor B (FB), factor P (FP; properdin), factor D (FD), factor H (FH), C3a and C5a levels were quantified by enzyme-linked immonosorbent assay in plasma and urine samples of patients with malignant nephrosclerosis and controls. Genetic abnormalities of complement components were analysed by whole-exome sequencing. Results Renal biopsies of malignant nephrosclerosis showed identical histopathological and ultrastructural features to atypical haemolytic uraemic syndrome. C5b-9, C3a and C5a deposits were found along the walls of arteries/arterioles and glomerular capillaries and localized in the endothelial cells. Elevated plasma and urinary levels of FB, FP, FD, C3a and C5a as well as decreased FH levels were observed in patients with malignant nephrosclerosis compared with normal controls. The urinary levels of complement AP components, but not the plasma levels, were correlated with renal functions, prognosis and active TMA lesions except for arteriolar thrombi. Finally, mutations of the MCP, CFB, CFH and CFHR5 genes were identified in 8 of 20 patients with malignant nephrosclerosis. Conclusions Aberrant complement AP dysregulation was demonstrated and associated with the activity, severity and renal outcomes of malignant nephrosclerosis. This observation warrants screening for complement defects in patients with malignant nephrosclerosis for the potential use of complement regulators and also highlights the need for further investigation of the precise role of AP in the pathogenesis of the disease.

Prevalence and prognosis of malignancy in THSD7A-associated membranous nephropathy: a systematic literature review and clinical case study

Risk and Prognostic Factors of Transplantation‐associated Thrombotic Microangiopathy in Allogeneic Haematopoietic Stem Cell Transplantation: a Nested Case Control Study

Evaluation the Risk Factor of Transplantation-Associated Thrombotic Microangiopathy.

SUN-030 PHOSPHOLIPASE A2 RECEPTOR AND THROMBOSPONDIN TYPE-1 DOMAIN-CONTAINING 7A IN MALIGNANCY MEMBRANOUS NEPHROPATHY

Features of Phospholipase A2 Receptor and Thrombospondin Type-1 Domain-Containing 7A in Malignancy-Associated Membranous Nephropathy

Membranous Nephropathy: Pathogenesis and Treatments

Circulating Antibodies Against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy.

A Novel Insight into the Role of PLA2R and THSD7A in Membranous Nephropathy

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient

THSD7A-associated membranous nephropathy involves both complement-mediated and autonomous podocyte injury

Specific antigens in malignancy-associated membranous nephropathy

Thromboembolic complications in membranous nephropathy patients with nephrotic syndrome-a prospective study.

Malignancy-associated Membranous Nephropathy: Focus on Diagnosis and Treatment

THSD7B Mutation Induces Platinum Resistance in Small Cell Lung Cancer Patients.

Characterization of THSD7A-antibodies not binding to glomerular THSD7A in a patient with diabetes mellitus but no membranous nephropathy

Integrated analysis of single-cell and bulk RNA-sequencing data reveals the prognostic value and molecular function of THSD7A in gastric cancer

Clinical characteristics of membranous nephropathy after allogeneic hematopoietic stem cell transplantation: A real-world multicenter study

Association between thrombotic microangiopathy and activated alternative complement pathway in malignant nephrosclerosis

Glomerular Hematuria as a Predictor of Renal Prognosis in Malignant Hypertension Patients with Thrombotic Microangiopathy: A Propensity Score-matched Analysis of a Biopsy-based Cohort Study

Clinical Features and Pathology of PLA2R and THSD7A-Associated Membranous Nephropathy: A Single-Center Study from China

Clinical Study of THSD7A, SOD2 and AR Antigens in Idiopathic Membranous Nephropathy